Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-14

Study Completion Date

2033-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer screening and prevention strategies. Traditional breast cancer risk assessments rely mostly on the presence of standard clinical risk factors including family history, reproductive history, and mammographic breast density. This information can be combined with validated risk estimation models to provide a measure of a patient's 10 year and lifetime risk for breast cancer. A polygenic risk score helps to estimate breast cancer risk in a more individualized way by evaluating a patient's genetics. Adding a polygenic risk score evaluation to traditional screening techniques may help minority women make more informed decisions about screening and prevention strategies for breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study

NCT04474834

Breast Cancer

ENROLLING_BY_INVITATION

Combined Breast Cancer Risk Study

NCT03067389

Hereditary Cancer

COMPLETED

Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer

NCT05158452

Breast Carcinoma

COMPLETED

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

NCT07207564

Breast Carcinoma

RECRUITING

Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot

NCT04002986

Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To explore if the addition of an individual polygenic risk score (PRS) to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will improve intentions to adhere to recommended breast cancer screening strategies such as mammography, magnetic resonance imaging (MRI), or molecular breast Imaging in women of underserved racial minorities.

II. To explore if the addition of the PRS to the BCRAT or IBIS risk score will aid women in deciding whether to take preventative endocrine therapy in women of racial minorities.

III. To understand how individualized risk assessment and information on PRS may alter perceived risk of breast cancer.

IV. To follow this cohort of women over 10 years to determine subsequent outcomes in regards to diagnoses of at-risk lesions or cancer.

OUTLINE: This is an observational study.

Patients complete a survey and undergo collection of a blood sample for PRS genotyping at baseline. Patients receive their PRS results and complete another survey 6 weeks to 6 months after baseline and then complete surveys annually over 10 years on study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Atypical Ductal Hyperplasia Breast Atypical Lobular Hyperplasia Breast Carcinoma Breast Lobular Carcinoma In Situ

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (blood collection, genotyping, surveys)

Patients complete a survey and undergo collection of a blood sample for PRS genotyping at baseline. Patients receive their PRS results and complete another survey 6 weeks to 6 months after baseline and then complete surveys annually over 10 years on study.

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of blood samples

Genotyping

Intervention Type PROCEDURE

Undergo genotyping

Survey Administration

Intervention Type OTHER

Complete surveys

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo collection of blood samples

Intervention Type PROCEDURE

Genotyping

Undergo genotyping

Intervention Type PROCEDURE

Survey Administration

Complete surveys

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection GENOTYPE Genotype Analysis Genotype Assay

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who self-identify as African American/Black or Hispanic/Latinx
* Women \>= 30 years old and =\< 75 years old
* Women with any of the following:

* IBIS (Tyrer-Cuzik) score of \>= 5% for the 10 year risk OR
* BCRAT (Gail Model) score of \> 3 % for the 5 year risk
* History of biopsy proven atypical ductal hyperplasia or atypical lobular hyperplasia (with risk calculator assessment A and B)
* History of biopsy proven lobular carcinoma in situ (with risk calculator assessment A and B)
* Able to participate in all aspects of the study
* Understand and signed the study informed consent

Exclusion Criteria

* Women whose calculated risk for breast cancer falls below the threshold
* Unable to give informed consent
* Prior history of invasive breast cancer, ductal carcinoma in situ or other breast cancers
* Women who are pregnant or breastfeeding
* Prior use of prevention drugs for longer than 6 months
* Prior risk reducing or prophylactic mastectomy
* Known pathogenic genetic mutation linked to breast cancer (such as BRCA 1/2, PALB2, ATM, CHEK2)

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No